FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3038940234> ?p ?o ?g. }

• W3038940234 endingPage "PR02" @default.
• W3038940234 startingPage "PR02" @default.
• W3038940234 abstract "Abstract Although high-grade serous ovarian cancers (HGSOC) are highly chemosensitive with an 85% initial response rate to platinum-based chemotherapy, 15% of patients are “exceptional nonresponders,” with platinum-refractory tumors that remain stable or progress during treatment. Unfortunately, we have no predictive biomarkers to identify refractory patients up front, and they receive futile chemotherapy through which most patients become too ill to be eligible for clinical trials. Hence, no progress has been made in treating these deadly tumors. The goal of this study is to identify mechanisms of platinum refractoriness to: i) predict refractory HGSOCs up front and ii) identify potential new drug targets in refractory disease to point to desperately needed new therapeutic approaches. Of note, 80-90% of patients who are initially platinum responsive will relapse and develop platinum-resistant disease, and it is possible that findings in platinum-refractory tumors might also provide insights into platinum-resistant tumors. Our NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC)-funded approach combines genomic and proteomic (“proteogenomic”) analyses of both preclinical models (0, 8, and 24 hours post-platinum exposure) and treatment-naïve human tumors. For preclinical models, we studied a well-characterized collection of patient-derived xenograft (PDX) models (10 sensitive, 10 refractory), as well as intrapatient HGSOC cell line pairs derived from patients before and after the development of platinum resistance. For the PDX models, proteogenomic profiling included RNASeq, WES, global proteomics, and phosphoproteomics at all 3 time points (0, 8, 24 hours). For cell line models (3 sensitive, 3 resistant), proteogenomic profiling was performed at all 3 timepoints (0, 8, 24 hours), and experiments were performed in complete biologic triplicate. Analyses included RNASeq, WES, global proteomics, phosphoproteomics, ubiquitin proteome, acetylated proteome, and pTyr. A large collection of 275 human HGSOCs (an approximate equal balance of platinum sensitive and refractory tumors) is currently undergoing proteomic profiling, and genomic profiles (WGS, RNASeq) will be performed on a subset. In parallel, we have performed a comprehensive review of 31 years of published work on platinum responses of human cancers, identifying ~700 genes implicated in the response and scoring each gene with respect to strength of the published evidence. Using a Bayesian approach, we are integrating the curated candidates from the literature with our empirical proteogenomic datasets to identify a candidate signature for detecting platinum-refractory disease prior to chemotherapy. We are also performing gene-regulatory network analysis to identify potential drivers of chemo response. NextGen, targeted, multiplex, multiple reaction monitoring mass spectrometry-based assays are being developed to quantify proteins in the signature for validation studies, using independent patient cohorts. This abstract is also being presented as Poster A62. Citation Format: Jacob J. Kennedy, Shrabanti Chowdhury, Sara R. Savage, Xiaonan Hou, Catherine J. Huntoon, Richard G. Ivey, Qing Yu, Chenwei Lin, Dongqing Huang, Lei Zhao, Uliana J. Voytovich, Regine M. Schoenherr, Zahra Shire, Steven J. Skates, Jeffrey R. Whiteaker, Andrew N. Hoofnagle, Samuel C. Mok, Bing Zhang, Larry M. Karnitz, S. John Weroha, Steven P. Gygi, Scott H. Kaufmann, Pei Wang, Michael J. Birrer, Amanda G. Paulovich. Proteogenomic approach to identify mechanisms of platinum refractoriness in high-grade serous ovarian cancers [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research; 2019 Sep 13-16, 2019; Atlanta, GA. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(13_Suppl):Abstract nr PR02." @default.
• W3038940234 created "2020-07-10" @default.
• W3038940234 creator A5006072228 @default.
• W3038940234 creator A5011271236 @default.
• W3038940234 creator A5021748600 @default.
• W3038940234 creator A5022925020 @default.
• W3038940234 creator A5023112522 @default.
• W3038940234 creator A5030218552 @default.
• W3038940234 creator A5031218554 @default.
• W3038940234 creator A5032550468 @default.
• W3038940234 creator A5040242042 @default.
• W3038940234 creator A5042220379 @default.
• W3038940234 creator A5042887409 @default.
• W3038940234 creator A5045473616 @default.
• W3038940234 creator A5048801471 @default.
• W3038940234 creator A5048878179 @default.
• W3038940234 creator A5049850046 @default.
• W3038940234 creator A5054370710 @default.
• W3038940234 creator A5055968334 @default.
• W3038940234 creator A5072278856 @default.
• W3038940234 creator A5073913471 @default.
• W3038940234 creator A5075958430 @default.
• W3038940234 creator A5075987044 @default.
• W3038940234 creator A5079793809 @default.
• W3038940234 creator A5081561534 @default.
• W3038940234 creator A5088406750 @default.
• W3038940234 creator A5091383290 @default.
• W3038940234 date "2020-07-01" @default.
• W3038940234 modified "2023-10-10" @default.
• W3038940234 title "Abstract PR02: Proteogenomic approach to identify mechanisms of platinum refractoriness in high-grade serous ovarian cancers" @default.
• W3038940234 doi "https://doi.org/10.1158/1557-3265.ovca19-pr02" @default.
• W3038940234 hasPublicationYear "2020" @default.
• W3038940234 type Work @default.
• W3038940234 sameAs 3038940234 @default.
• W3038940234 citedByCount "0" @default.
• W3038940234 crossrefType "journal-article" @default.
• W3038940234 hasAuthorship W3038940234A5006072228 @default.
• W3038940234 hasAuthorship W3038940234A5011271236 @default.
• W3038940234 hasAuthorship W3038940234A5021748600 @default.
• W3038940234 hasAuthorship W3038940234A5022925020 @default.
• W3038940234 hasAuthorship W3038940234A5023112522 @default.
• W3038940234 hasAuthorship W3038940234A5030218552 @default.
• W3038940234 hasAuthorship W3038940234A5031218554 @default.
• W3038940234 hasAuthorship W3038940234A5032550468 @default.
• W3038940234 hasAuthorship W3038940234A5040242042 @default.
• W3038940234 hasAuthorship W3038940234A5042220379 @default.
• W3038940234 hasAuthorship W3038940234A5042887409 @default.
• W3038940234 hasAuthorship W3038940234A5045473616 @default.
• W3038940234 hasAuthorship W3038940234A5048801471 @default.
• W3038940234 hasAuthorship W3038940234A5048878179 @default.
• W3038940234 hasAuthorship W3038940234A5049850046 @default.
• W3038940234 hasAuthorship W3038940234A5054370710 @default.
• W3038940234 hasAuthorship W3038940234A5055968334 @default.
• W3038940234 hasAuthorship W3038940234A5072278856 @default.
• W3038940234 hasAuthorship W3038940234A5073913471 @default.
• W3038940234 hasAuthorship W3038940234A5075958430 @default.
• W3038940234 hasAuthorship W3038940234A5075987044 @default.
• W3038940234 hasAuthorship W3038940234A5079793809 @default.
• W3038940234 hasAuthorship W3038940234A5081561534 @default.
• W3038940234 hasAuthorship W3038940234A5088406750 @default.
• W3038940234 hasAuthorship W3038940234A5091383290 @default.
• W3038940234 hasConcept C104317684 @default.
• W3038940234 hasConcept C121608353 @default.
• W3038940234 hasConcept C126322002 @default.
• W3038940234 hasConcept C142424586 @default.
• W3038940234 hasConcept C143998085 @default.
• W3038940234 hasConcept C182979987 @default.
• W3038940234 hasConcept C2776694085 @default.
• W3038940234 hasConcept C2779962180 @default.
• W3038940234 hasConcept C2994294914 @default.
• W3038940234 hasConcept C46111723 @default.
• W3038940234 hasConcept C502942594 @default.
• W3038940234 hasConcept C55493867 @default.
• W3038940234 hasConcept C60644358 @default.
• W3038940234 hasConcept C71924100 @default.
• W3038940234 hasConcept C82381507 @default.
• W3038940234 hasConcept C86803240 @default.
• W3038940234 hasConcept C87355193 @default.
• W3038940234 hasConceptScore W3038940234C104317684 @default.
• W3038940234 hasConceptScore W3038940234C121608353 @default.
• W3038940234 hasConceptScore W3038940234C126322002 @default.
• W3038940234 hasConceptScore W3038940234C142424586 @default.
• W3038940234 hasConceptScore W3038940234C143998085 @default.
• W3038940234 hasConceptScore W3038940234C182979987 @default.
• W3038940234 hasConceptScore W3038940234C2776694085 @default.
• W3038940234 hasConceptScore W3038940234C2779962180 @default.
• W3038940234 hasConceptScore W3038940234C2994294914 @default.
• W3038940234 hasConceptScore W3038940234C46111723 @default.
• W3038940234 hasConceptScore W3038940234C502942594 @default.
• W3038940234 hasConceptScore W3038940234C55493867 @default.
• W3038940234 hasConceptScore W3038940234C60644358 @default.
• W3038940234 hasConceptScore W3038940234C71924100 @default.
• W3038940234 hasConceptScore W3038940234C82381507 @default.
• W3038940234 hasConceptScore W3038940234C86803240 @default.
• W3038940234 hasConceptScore W3038940234C87355193 @default.
• W3038940234 hasIssue "13_Supplement" @default.
• W3038940234 hasLocation W30389402341 @default.
• W3038940234 hasOpenAccess W3038940234 @default.

• next